Tiazolidindiony: pol'za ili risk?
https://doi.org/10.14341/2072-0351-5869
Abstract
Тиазолидиндионы (ТЗД) или глитазоны? были впервые предложены в качестве препаратов для лечения сахарного диабета 2 типа (СД 2) в 1996 г. Механизмом их действия является увеличение чувствительности к инсулину, т. е. воздействие на один из ключевых компонентов патогенеза СД 2 ? инсулинорезистентность.
References
1. Bloomgarden Z. Thiazolidinediones // Diabetes Care, Vol. 28, N.2, Feb. 2005, 488-493.
2. Boggs W. Higher Cancer Prevalence Seen Among Diabetics Taking Thiazolidinediones // Reuters Health Information 2007. © 2007 Reuters Ltd
3. Charbonnel B., Dormandy J., Erdmann E. et al. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients // Diabetes Care, Vol. 27, N.7, Jul. 2004, 1647-1653.
4. Davidson M. Clinical Implications of the DREAM Study // Diabetes Care, Vol. 30, N.2, Feb. 2007, 418-420.
5. European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Press Release // London, 18 October 2007 Doc. Ref. EMEA/484277/2007
6. Hughes S. Cochrane Review Urges Caution on Rosiglitazone Use // Heartwire 2007. © 2007 Medscape
7. Hughes S. Glitazones Increase Heart Failure but Not Mortality in New Meta-Analysis // Heartwire 2007. © 2007 Medscape
8. Hughes S. Rosiglitazone Increases MI and CV Death in Meta-Analysis// Heartwire 2007. © 2007 Medscape
9. Kendall D. Thiazolidinediones. The case for early use // Diabetes Care, Vol. 29, N.1, Jan. 2006, 154-157.
10. Lago R., Singh P., Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials // Lancet 2007; 370: 1129-36
11. Nesto R., Bell D., Bonow R. et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure A consensus statement from the American Heart Association and American Diabetes Association // Diabetes Care, Vol. 27, N.1, Jan. 2004, 256 - 263.
12. O'Riordan M. ADOPT Analysis Shows Rosiglitazone Increases Risk of Fracture in Women // Heartwire 2007. © 2007 Medscape
13. Patel C., De Lemos J., Wyne K., McGuire D. Thiazolidinediones and risk foratherosclerosis: pleiotropic effects of PPAR agonism // Diabetes Vasc Dis Res 2006;3:65-71
14. Rizza R., Henry R., Kahn R. Commentary on the Results and Clinical Implications of the PROactive Study // Diabetes Care, Vol. 28, N.12, Dec. 2005, 2965-2967.
15. Staels B., Fruchart J. Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists // Diabetes, Vol.54, Aug. 2005, 2460-2470.
16. Schwartz A., Sellmeyer D., Vittinghoff E. et al. Thiazolidinedione Use and Bone Loss in Older Diabetic Adults // The Journal of Clinical Endocrinology & Metabolism 91(9):3349-3354
17. Schwartz A., Sellmeyer D. Thiazolidinedione Therapy Gets Complicated Is bone loss the price of improved insulin resistance? // Diabetes Care 30:1670-1671, 2007
18. Viberti G., Kahn S., Greene D. et al. A Diabetes Outcome Progression Trial (ADOPT) An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes // Diabetes Care, Vol. 25, N. 10, Oct 2002, pp. 1737- 1743
19. Watts N., D'Alessio D. Type 2 Diabetes, Thiazolidinediones: Bad to the Bone? // The Journal of Clinical Endocrinology & Metabolism 91(9):3276-3278
20. Wilding J. Thiazolidinediones, Insulin Resistance And Obesity: Finding A Balance // Int J Clin Pract. 2006;60(10):1272-1280.
Review
For citations:
Severina A.S. Tiazolidindiony: pol'za ili risk? Diabetes mellitus. 2007;10(4):58-62. (In Russ.) https://doi.org/10.14341/2072-0351-5869
Views:
20986
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
